Zobrazeno 1 - 10
of 183
pro vyhledávání: '"S-A Im"'
Autor:
Joohyuk Sohn, S.-B. Kim, Konstantinos Tryfonidis, A. Wang, Peter Schmid, Eva Muñoz-Couselo, Lina Yin, Roberto Salgado, Rebecca Dent, Sherene Loi, S-A. Im, Vassiliki Karantza, J. Cortes, Sherko Kuemmel, Theodoros Foukakis, Younghee Park
Publikováno v:
Annals of Oncology. 31:569-581
Background The phase Ib KEYNOTE-173 study was conducted to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy plus pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC). Patients an
Autor:
S. Malwinder, Rebecca Dent, Fatima Cardoso, Yongmei Yin, H. Iwata, Shigehira Saji, Tatsuya Toyama, Tae Yong Kim, Yung-Feng Lu, Soo-Chin Lee, Sudeep Gupta, Jihyeung Kim, Georgios Pentheroudakis, J.-Y. Douillard, M. Y. Mastura, B.K. Smruti, S.-A. Im, Elżbieta Senkus-Konefka, Takayuki Yoshino, Young-Ae Park, L-M Tseng, Koung Jin Suh
Publikováno v:
Annals of Oncology. 31:451-469
In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at th
Autor:
Roberto Buzzoni, W.P. Yong, S. Reingold, Joseph McKendrick, G.J.M. Creemers, Fernando Rivera, Dewi Vernerey, David Cunningham, G. Ravit, E. Van Cutsem, Jin-Tung Liang, A. de Gramont, Pia Österlund, G. Bodoky, Thierry André, J. Tabernero, W. Scheithauer, Randi Isaacs, Manel Rakez, S-A. Im, G. Fountzilas
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Annals of Oncology, Elsevier, 2020, 31, pp.246-256. ⟨10.1016/j.annonc.2019.12.006⟩
Background The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon cancer (CC). We report here
Autor:
Peter Schmid, J. Cortes, Giuseppe Curigliano, N. Turner, Sara A. Hurvitz, E. de Azambuja, S. Loibl, D. Krug, Deborah Fenlon, S. Paluch-Shimon, Mark E. Robson, S-A. Im, Carlos H. Barrios, Christian F. Singer, W.G. Kunz, Rebecca Dent, Sara M. Tolaney, Fabrice Andre, Joseph Gligorov, Sherene Loi, Angela DeMichele, Frédérique Penault-Llorca, Tanja Spanic, Jens Ricke, Hope S. Rugo, Cristina Saura, Alessandra Gennari, Nadia Harbeck
Publikováno v:
Annals of Oncology
Annals of Oncology, Elsevier, 2021, ⟨10.1016/j.annonc.2021.09.019⟩
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Annals of Oncology, Elsevier, 2021, ⟨10.1016/j.annonc.2021.09.019⟩
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Sin financiación 32.976 JCR (2020) Q1, 7/242 Oncology 8.590 SJR (2021) Q1, 2/133 Hematology No data IDR 2020 UEM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4f85d47e005f4f53021deb511dd030
https://hal.archives-ouvertes.fr/hal-03428164
https://hal.archives-ouvertes.fr/hal-03428164
Autor:
J.-H. Jang, Y.H. Park, M.S. Park, Yee Soo Chae, J.-Y. Kim, K.S. Lee, J. Sohn, S.-Y. Lee, E.H. Cho, S.-A. Im, J.H. Kim, K.H. Jung, J.H. Ahn, K.H. Lee
Publikováno v:
ESMO Open
Background In this study, we evaluated the association between genetic polymorphisms of 23 genes associated with gemcitabine metabolism and the clinical efficacy of gemcitabine in breast cancer patients. Patients and methods This prospective, pharmac
Autor:
JT Beck, Arunava Chakravartty, U. Deore, Craig Wang, Y. Ji, Juan Pablo Zarate, K. Petrakova, G. Valeria Bianchi, Arnd Nusch, Patrick Neven, S-A. Im, S Chia, Tanya Taran, Gabe S. Sonke, Miguel Martin, Guy Jerusalem, Peter A. Fasching, Dennis J. Slamon, M. De Laurentiis, L. de la Cruz-Merino
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(8)
BACKGROUND: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced bre
Publikováno v:
Frontiers in Education, Vol 6 (2021)
Chemistry education is challenging when many students cannot see the relevance and interest between what they learn at school and their everyday life outside the curriculum. Due to the prevalence of chemicals in real life, students lose interest in t
Autor:
C. Goessl, Susan M. Domchek, Suzette Delaloge, W. Wu, S-A. Im, Mark E. Robson, Norikazu Masuda, Binghe Xu, Nadine Tung, Elżbieta Senkus, Pierfranco Conte, Andrew J. Armstrong, Wei Li, Sarah Runswick
Publikováno v:
Annals of Oncology
Background In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth fa
Autor:
S-A Im, Hua Li, Paul A. Moore, Y-J. Bang, Jeffrey L. Nordstrom, Giuseppe Giaccone, D-Y. Oh, Edwin P. Rock, Todd M. Bauer, Jan Baughman, Shengyan Hong, H. A. Burris
Publikováno v:
Cancer Research. 79:P6-18
Background Margetuximab is an Fc-optimized anti-HER2 antibody that recognizes the same epitope as trastuzumab. Margetuximab has increased affinity for the activating CD16A Fc-receptor on NK cells and macrophages as well as decreased affinity for the
Autor:
Debu Tripathy, S-A Im, Aditya Bardia, Francisco J. Esteva, M. Campone, S Chia, W Bao, O Kong, Andrew T. Chan, D. A. Yardley, I Diaz-Padilla, H. A. Burris, K Rodriguez Lorenc
Publikováno v:
Cancer Research. 79:P6-18
Background: In Phase III trials, ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + various endocrine therapy (ET) partners has demonstrated significantly prolonged progression-free survival vs placebo (PBO) + ET in patients (pts) with hormone